Pharma-Bio Serv, Inc. reported its financial results for the second quarter of fiscal year 2026, revealing a total revenue of $2.7 million for the three months ending April 30, 2026, an increase of approximately 11.8% compared to $2.4 million for the same period in 2025. For the six-month period, revenues reached $5.0 million, reflecting a modest increase of 2.2% from $4.9 million in the prior year. The company achieved a net income of $233,000 for the quarter, up from $95,000 in the previous year, and a net income of $266,000 for the six months, compared to $104,000 in the same period last year. Basic and diluted earnings per share for the quarter were $0.010 and $0.012, respectively, both showing significant improvement from the previous year.
The financial performance indicates a strategic shift, particularly in the Puerto Rico consulting segment, which saw a revenue increase of $281,000 for the quarter and $342,000 for the six months. This growth was partially offset by a decline in the United States consulting segment, which experienced a revenue decrease of $94,000 for the quarter and $193,000 for the six months. The Europe consulting segment also contributed positively, with a revenue increase of $93,000 for the quarter, although it showed a slight decline for the six-month period.
Operationally, Pharma-Bio Serv has made significant changes, including the transition of its headquarters to a virtual landscape following the expiration of its office lease in December 2025. This move is expected to enhance operational efficiency and reduce overhead costs. The company continues to focus on expanding its market presence in Puerto Rico, the United States, Europe, and Brazil, leveraging its expertise in compliance consulting for the pharmaceutical and biotechnology sectors. As of April 30, 2026, the company reported a total of 23,519,672 shares outstanding, with a treasury stock of 617,980 shares.
The company’s total assets decreased to $11.5 million as of April 30, 2026, down from $13.7 million at the end of the previous fiscal year, primarily due to a reduction in cash and cash equivalents. Current liabilities also decreased significantly to $1.0 million from $1.7 million, largely due to a reduction in tax liabilities. The company’s working capital stood at approximately $10.2 million, indicating a solid liquidity position to meet its operational needs.
Looking ahead, Pharma-Bio Serv remains cautiously optimistic about its growth trajectory, despite potential challenges posed by economic conditions, regulatory changes, and industry competition. The company plans to continue enhancing its business development efforts and adapting its strategies to capitalize on emerging opportunities in the compliance consulting market. Management believes that the current level of working capital and operational cash flows will be sufficient to support its anticipated expenses and commitments over the next twelve months.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv provides compliance consulting services to the pharmaceutical, biotech, medical device, cosmetic, and food industries. Its core offerings include regulatory compliance, validation, technology transfer, and engineering services across Puerto Rico, the U.S., Europe, and Brazil. The company leverages experienced professionals to serve major clients, focusing on quality, regulatory adherence, and market expansion within a fragmented, competitive industry.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.